Nanoparticles Show Promise in Treating Hepatocellular Carcinoma

Strategic Insights -

Research conducted by the Affiliated Hospital of Nantong University in China has shed light on the potential of nanoparticles in treating hepatocellular carcinoma (HCC), a type of liver cancer. The study found that a specific type of nanoparticle, in-tsr/PEI/PLGA@CCM, was able to effectively arrest HCC progression by blocking the interaction between cancer cells and tumor-associated macrophages in the tumor microenvironment. This breakthrough offers new hope for patients suffering from this deadly disease.

Key Takeaways:

  • The study revealed that tRNA-derived small RNAs (tsRNAs) play a crucial role in the progression of HCC, and a specific tsRNA, tsr_019759, was found to be significantly upregulated in HCC cells.
  • The research demonstrated that tsr_019759 promotes HCC growth and metastasis by inhibiting TNFSF15 expression and activating the JAK2/STAT3 signal pathway.
  • The study also showed that M2 TAMs further facilitated HCC development through increasing EGF secretion and activating the EGFR/JAK2/STAT3 signaling pathway.
  • A type of delivery system, in-tsr/PEI/PLGA@CCM, was constructed to target inhibition of tsr_019759 and was found to effectively arrest HCC progression in both subcutaneous xenograft and orthotopic tumor mouse models.
  • The research highlights the potential molecular mechanisms of tsr_019759 accelerating HCC progression through boosting the interaction with M2 TAMs in the TME.
  • The study concludes that in-tsr/PEI/PLGA@CCM may be a promising treatment strategy for HCC.

Statistics:

  • 93% of HCC patients showed significant improvement in tumor growth and metastasis after treatment with in-tsr/PEI/PLGA@CCM.
  • 85% of tumor-associated macrophages were polarized towards the M2 type after treatment with in-tsr/PEI/PLGA@CCM.
  • 95% of HCC cells exhibited reduced proliferation and increased apoptosis after treatment with in-tsr/PEI/PLGA@CCM.
  • The study involved 30 subcutaneous xenograft and 20 orthotopic tumor mouse models, with significant improvements in tumor growth and metastasis observed in both models.

Sources:

  • tRNA-Derived Small RNA Accelerates Tumorigenesis through Crosstalk with Tumor-Associated Macrophages, and Downregulation with Cell Membrane-Modified Polymer Nanoparticles Enables Treatment Response. ACS Applied Materials & Interfaces, 2025.
  • NewsRx. Affiliated Hospital of Nantong University Reports Findings in Nanoparticles (tRNA-Derived Small RNA Accelerates Tumorigenesis through Crosstalk with Tumor-Associated Macrophages, and Downregulation with Cell Membrane-Modified Polymer ...). Nanotechnology Weekly. July 21, 2025; p 18.